| KHC |
Report |
Organic net sales growth |
BEAT |
pred ~(3.2)% vs. cons (3.5)% |
MEDIUM |
| KHC |
Report |
Adjusted EBITDA |
BEAT |
pred ~$1.30B vs. cons $1.28B |
MEDIUM |
| KHC |
Report |
Adjusted EPS |
BEAT |
pred ~$0.55 vs. cons $0.53 |
MEDIUM |
| KHC |
Guide |
FY26 organic net sales growth |
UNCHANGED |
guide ~(1.5)% to (3.5)% vs. cons ~(2.5)% (FY26) |
MEDIUM |
| KHC |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide ~$1.98 to $2.10 vs. cons $2.04 (FY26) |
MEDIUM |
| KHC |
Guide |
FY26 adjusted gross-margin change |
UNCHANGED |
guide ~(25) to (75) bps vs. cons ~(50) bps (FY26) |
LOW |
| KHC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
MEDIUM |
| KHC |
Return |
5-day cumulative residual |
+4.0% (FOLLOW-THROUGH) |
A ~3.0% day-1 residual reaction should extend toward ~4.0% over five days if a modest 2Q beat is paired with unchanged FY26 guide math, improving share commentary, and no implied out-period EPS cut. |
MEDIUM |